Fulgent Genetics Inc (FLGT) Q3 2024 Earnings Call Highlights: Strategic Growth Amid Revenue Decline
Brandon Perthuis, Chief Commercial Officer, discusses the $99 million VA contract's phased contribution over five years, expecting significant input by 2025. Paul Kim, CFO, notes improved gross margins at 40%, with SG&A favorably impacted and R&D spending varying with program activities.